dog on the beach

News

Invetx: Now a division of Dechra

In July 2024 Dechra Pharmaceuticals acquired Invetx.
Invetx continues its focus to bring differentiated biotherapeutics for dogs and cats to Animal Health market as its own Division within the Dechra organization.

PETS: A LEAP FORWARD FOR VETERINARY CARE

Global pet populations continue to grow and their role has evolved into being an integral part of the family. Like humans, dogs and cats are living longer and their continued health and quality-of-life is a tremendous concern for pet owners. At Invetx, our goal is to drastically elevate the standard of care for animal diseases and chronic conditions such as pain, allergy, cancer and diabetes. Biopharmaceuticals provide the opportunity to deliver highly targeted, effective and safe therapies for pets, while at the same time relieving pet owners from the burden of daily administration.

animals 01 v2
Dots
invetx antibody transparent circle v2
Dots
Dots

AN INNOVATIVE TEAM AND AN ATTRACTIVE PARTNER

Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health. We partner with best-in-class biotechnology companies to apply their deep expertise and extensive capabilities for the discovery and development of novel and advanced veterinary biotherapeutics.

Our team of highly experienced R&D leaders from both human biotech and animal health is focused on guiding the development of an exciting portfolio of therapies for a new standard of care. We further benefit from an extensive network of industry experts and work closely with veterinary scientists and clinicians.

Invetx is backed by dedicated investors and has a unique cross-disciplinary team which makes it an attractive partner for companies and experts and a highly dynamic and rewarding work place.

CONTACT US

Invetx
ABI Lab
22 Strathmore Road
Natick, MA, 01760, USA
info@invetx.com

Dots
Invetx